Cancer immunotherapy: Recent breakthroughs and perspectives;Immunothérapie des cancers: Succès récents et perspectives

Medecine/Sciences

Volumn 27, Issue 10, 2011, Pages 833-841

  Tartour, Éric ^a,b   Sandoval, Federico ^a   Bonnefoy, Jean Yves ^c   Fridman, Wolf H ^b,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c TRANSGENE S A   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; EXPERIMENTAL THERAPY; FORECASTING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PRECANCER; REVIEW; SURVIVAL; T LYMPHOCYTE SUBPOPULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PRECANCEROUS CONDITIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; THERAPIES, INVESTIGATIONAL;

EID: 80455123666     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20112710011     Document Type: Review

References (60)

1. Tartour E, Mathiot C, Fndman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46 :473-84. (Pubitemid 23041384)
2. Abes R, Gelize E, Fridman WH, et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116: 926-34.
3. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumob and chemotherapy. Clin Cancer Res 2007;13:5133-43. (Pubitemid 47502081)
4. Bodmer A, Goetsch L, Favet L, et al. Anticorps et tumeurs solides: cibles etablies et pistes prometteuses. Med Sci (Paris) 2009;25:1090-8.
5. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102.
6. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. CurrOpin Immunol 2009; 21:233-40.
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 :411-22.
8. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27.
9. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29 : 2787-94.
10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
11. Atkins MB. Treatment selection for patients with metastatic renal cell carcinoma : identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 2009; 26 (suppl 1): 18-22.
12. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82. (Pubitemid 32730084)
13. Rosenberg SA, yangJC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909-15. (Pubitemid 39273730)
14. Kaicheur N, Escudier B, Dorval T, et al. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000; 119: 28-37. (Pubitemid 30064588)
15. Tartour E, Blay jy, Dorval T, et al. Predictors of clinical response to interleukin-2. Based immunotherapy in melanoma patients: a French multiinstitutional studyj Clin Oncol 1996 ; 14 :1697-703. (Pubitemid 26134229)
16. Derhovanessian E, Adams V, Hahnel K, et al. Pretreatment frequency of circulating IL-17. CD4. T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009 ; 125 :1372-9.
17. th, 2010.; J Clin Oncol 2010; 28:2609 (abstract).
18. Shrimali RK, yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80.
19. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.; J Clin Oncol 2009; 27 : 2645-52.
20. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429-40.
21. Gajewski TF, Fuertes M, Spaapen R, et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2010 ; 23 : 286-92.
22. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens J Exp Med 2005 ; 201: 241-8. (Pubitemid 40189433)
23. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with J Clinical response in dendritic cell-based immunotherapy for malignant melanoma. J Clin Cancer Res 2003;9:998-1008. (Pubitemid 36323703)
24. Acres B, Bonnefoy jy. J Clinical development of MVA-based therapeutic cancer vaccines. Exp Rev Vaccines 2008 ; 7 : 889-93.
25. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47.
26. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008 ; 8 : 351-60. (Pubitemid 351589701)
27. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.; J Clin Oncol 2009; 27: 3036-43.
28. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme : pilot results leading to Phase III J Clinical development. Vaccine 2007 ; 25 (suppl 2): B61-71. (Pubitemid 47488551)
29. Peoples GE, GurneyJM, Hueman MT, et al. J Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.; J Clin Oncol 2005 ; 23 : 7536-45. (Pubitemid 46291817)
30. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. ; J Natl Cancer Inst 2010 ; 102 :1388-97.
31. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer.; J Clin Oncol 2010 ; 28 :1099-105.
32. van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.; J Clin Oncol 2005;23:9008-21. (Pubitemid 46211485)
33. Gogas H, loannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354 : 709-18. (Pubitemid 43247141)
34. Bouwhuis MG, Ten Hagen TL, Suciu S, et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2010; 23:170-6.
35. Attia P, Phan GO, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.; J Clin Oncol 2005 ; 23:6043-53.
36. Nelson BH. CD20. B cells : the other tumor-infiltrating lymphocytes.; Immunol 2010; 185 : 4977-82.
37. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Mud-112) in association with chemotherapy in patients with stage 11 l/l V Non-small cell lung cancer.; Thome Oncol 2008; 3:735-44.
38. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.; J Immunother 2008; 31:101-12. (Pubitemid 351619409)
39. Leibundgut-Landmann S, Osorio F, Brown GD, et al. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 2008 ; 112 :4971-80.
40. Berraondo P, Nouze C, Preville X, et al. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007 ; 67 : 8847-55. (Pubitemid 47437461)
41. Adotevi 0, Vingert B, Freyburger L, et al. B Subunit of Shiga toxin-based vaccines synergize with (alpha)-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. ; J Immunol 2007; 179 : 3371-9.
42. Vingert B, Adotevi 0, Patin D, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006 ; 36 :1124-35.
43. Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.; J Clin Invest 2009; 119 : 2648-62.
44. Welters MJ, Kenter GG, De Vos Van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010; 107 : 11895-9.
45. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8' T cell dysfunction in melanoma patients.; Exp Med 2010 ; 207 : 2175-86.
46. Derre L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumorspecific CD8. T cells that can be partially reversed by vaccination.; J Clin Invest 2010; 120:157-67.
47. Badoual C, Bouchaud G, Agueznay Nel H, et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008; 68 : 3907-14.
48. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistancej J Clin Invest 2010 ; 120 :1285-97.
49. Zitvogel L, Kepp 0, Kroemer G. Decoding cell death signals in inflammation and immunity Cell 2010; 140 : 798-804.
50. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008 ; 8 : 59-73.
51. Lee y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8 T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-95.
52. Gabnlovich Dl, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. J Clin Cancer Res 1999; 5 : 2963-70. (Pubitemid 29493976)
53. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitmib-based antiangiogenic therapy in metastatic renal cancer patients.; Immunother 2010; 33: 991-8.
54. Ko JS, Zea AH, Rini Bl, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. J Clin Cancer Res 2009; 15 : 2148-57.
55. Huang KW, Wu HL, Lin HL, et at. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc Natl Acad Sci USA 2010; 107 :14769-74.
56. Abès R, Dutertre CA, Teillaud JL Les anticorps: mieux les connaître pour mieux s'en servir. Med Sci (Paris) 2009 ; 25 :1011-9
57. Robert C, Mateus C. Anticorps anti-CTLA 4 : une avancée thérapeutique majeure dans le traitement du melanome metastatique. Med Sci (Paris) 2011;27:850-8.
58. Apetoh L, Ghiringhelli F, Zitvogel L. La calreticuline détermine I'lmmunogénicité de la chimiothérapie et de la radiothérapie antitumorales . Med Sci (Paris) 2007; 23 : 257-8.
59. Rousseaux S, Reynoird N, Gaucher J, Khochbin S. L'intrusion des régulateurs de I'épigénome mâle dans les cellules somatiques cancéreuses. Med Sci (Paris) 2008 ; 24: 735-41.
60. Olive D, le Thi S, Xerri L, et al. Role de CTLA-4 dans la cosignalisation négative du système immunitaire. Med Sci (Paris) 2011; 27: 842-9.